Markets

Stocks

Are traders getting too optimistic?

Jason Rotman, Lido Isle Advisors managing partner, and Kevin Kelly, Recon Capital chief investment officer, discuss two-straight days of triple-digit gains on the Dow, what the market rally means for future rate hikes, and where to allocate capital.

Should Investors Be Excited About Sarepta's Delay?

After the FDA announced that it would need more time to complete its review of Sarepta Therapeutics ' controversial therapy for a rare form of muscular dystrophy, investors clamored to buy the company's shares, sending themsoaring by 26.6% today.

ETFs

Earnings

Best Buy Forecasts Profit Miss, CFO to Step Down

Best Buy forecast current-quarter profit below analysts' estimates, partly due to a disruption in supply of some high-margin products after an earthquake in Japan, and the company said its chief financial officer was stepping down.